CD8A and neoplasm: Researchers have found that CD8+ TILs at different tumor sites have diverse clinical attributes and a number of factors in the TME, such as the activation of inhibitory checkpoint pathways, abnormal tumor angiogenesis, and chemokine secretions, can exactly suppress the function of CD8+ TILs (33).